Medify Solutions Ltd.

Medify Solutions Limited (Pink Sheets MFYS) Explains the Sales Potential for UK Remote Access Market

    Gateshead, England (ots/PRNewswire) - On the 1st September 2006, Medify Solutions Limited will roll out its  'remote access to patient notes' product, MedifyRemote, to its National  Health Service (NHS) customers. The first NHS site, as published previously , will be in Doncaster in the north of England.

    This site is leading the way for the rest of the UK in terms of development and user testing of the powerful Medify Remote live product,  which will bring many benefits for patients and users in terms of greater  efficiency and more accurate transfer of information.

    Operating through its N3 approved secure connection to the NHS patient  database; Medify will begin the roll out to its live NHS customers. This  will be coordinated through corporate partners who are providing the  patient record software and airtime connection to the NHS.

    The sales potential for Medify Remote is significant. For ease of understanding, the product will be offered to the customer at a monthly  charge in the region of US$85 per month. In the UK there are over 500 000  healthcare professionals, the primary target user. Thus the market for  Medify in the UK alone is US$510m per annum (85 x 500 000 x 12).

    Therefore for every 1% market penetration, the revenue for Medify is $ 5.1m per annum.

    Medify has the approved connection to NHS' N3, the secure national IT  network and has contracts to provide the service to NHS Healthcare  professionals, which will now roll out over the next 12 months. As the only  provider to offer the service Medify is set to achieve significant revenues  starting on the 1st of September 2006.

    Of further importance is that UK Healthcare professionals represent  approximately 10% of the overall European market and approximately 1% of a  total global market of 59 million professionals (potential users).

    Contact :

    Company website :

    This news release contains forward-looking statements that are subject  to certain risks and uncertainties that may cause actual results to differ  materially from those projected on the basis of such forward-looking  statements. The words "estimate," "project," "intends," "expects," " believes," and similar expressions are intended to identify forward-looking  statements. Such forward-looking statements are made based on management's  beliefs, as well as assumptions made by, and information currently  available to, management pursuant to the "safe-harbour" provisions of the Private Securities Litigation Reform Act of 1995. For a more complete description of these and other risk factors that may affect the future  performance of Medify Solutions Limited, see "Risk Factors" in the  Company's Annual Report on Form 10-KSB and its other filings with the  Securities and Exchange Commission. Readers are cautioned not to place  undue reliance on these forward-looking statements, which speak only as of  the date made and the Company undertakes no obligation to disclose any  revision to these forward-looking statements to reflect events or  circumstances after the date made or to reflect the occurrence of  unanticipated events.

ots Originaltext: Medify Solutions Ltd.
Im Internet recherchierbar:

For further information: Jonathan Bryant, Group Chairman, Medify
Solutions, Tel: +44-(0)845-034-4090, Fax: +44-(0)1785-214474,

Weitere Meldungen: Medify Solutions Ltd.

Das könnte Sie auch interessieren: